- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06205134
Comparative Bioavailability of Intranasal Epinephrine
A Study to Compare the Bioavailability of Epinephrine Following a Single Nasal Dose of FMXIN002 Microspheres Powder 3.6mg, and 4mg With EpiPen 0.3mg Intramuscular Injection in Healthy Adults
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
An open-label trial in 12 healthy adults. FMXIN002 (3.6 mg and 4.0 mg) will be administered intranasally to healthy adults and compared to IM (0.3mg, EpiPen) by Epinephrine pharmacokinetics, pharmacodynamic response and clinical safety.
(https://my.health.gov.il/CliniTrials/Pages/MOH_2023-07-01_012776.aspx.)
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Jerusalem, Israel, 91120
- Clinical Pharmacology Unit, Hadassah Medical Center, Ein Karem
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
1) Non-smoking, male and female subjects from 18 to 55 years of age. 2) BMI ≥18 < 30 kg/m2. 3) Females may be of childbearing or non-childbearing potential:
Childbearing potential:
o Physically capable of becoming pregnant, must be willing to use acceptable effective methods of contraception
Non-childbearing potential:
- Surgically sterile
Postmenopausal (no menstrual period for at least 12 consecutive months without any other medical cause).
4) Able to tolerate venipuncture. 5) Be informed of the nature of the study and give written consent prior to any study procedure.
6) Willing and being able to remain in the clinic for the entire duration of the confinement period.
7) Have good intravenous access on both arms and hands.
Exclusion Criteria:
1) Known history or presence of clinically significant neurologic, hematologic, endocrine, oncologic, pulmonary, immunologic, genitourinary, psychiatric, ischemic heart disease or Arteriosclerosis or cardiovascular disease, autoimmune disease, or Raynaud Phenomenon and any other condition which, in the opinion of the Investigator, would jeopardize the safety of the subject or impact the validity of the study results.
- Known history or presence of hypersensitivity or idiosyncratic reaction to epinephrine, sulfite, other excipients of epinephrine auto-injector, or any other drug substances with similar activity.
- Known history or presence of clinically significant lactose, galactose, or fructose allergy
- Known history or presence of any food allergy.
- Presence of nostril or septum piercing.
- Presence of abnormal nasal anatomy (e.g., polyps, unilateral or bilateral abnormalities of the nares, nasal turbinates, or septum including deviated septum).
- History of nasal surgery.
- Presence of a medical condition requiring regular medication (prescription and/or over-the-counter) with systemic absorption other than oral contraceptives.
- History of drug or alcohol addiction requiring treatment or positive alcohol breath test at check-in.
- Any acute illness (e.g. cold, acute infection) which is considered significant by the Investigator and that has not resolved within 7 days before the first drug administration.
- Positive test result for HIV, Hepatitis B surface antigen, or Hepatitis C antibody.
- Positive test result for urine drugs of abuse (amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine, methadone, opiates, phencyclidine, and tricyclic antidepressants) or urine cotinine.
- Inability to communicate well with the Investigators and staff
- Non-cooperative or unwilling to sign consent form or unwilling to attend scheduled clinic visits and/or comply with the study protocol.
- Use of tobacco or nicotine-containing products within 6 months prior to drug administration.
Females who:
- Have discontinued or changed the use of implanted, intrauterine, intravaginal, or injected hormonal contraceptives within 6 months prior to drug administration;
- Have discontinued or changed the use of oral or patch hormonal contraceptives within 1 month prior to drug administration;
- Are pregnant (Urine hCG consistent with pregnancy); or
- Are lactating.
Donation or loss of whole blood (including clinical trials):
- ≥50 mL and <500 mL within 30 days prior to drug administration;
- ≥500 mL within 56 days prior to drug administration.
- Participation in a clinical trial that involved administration of an investigational medicinal product within 30 days prior to drug administration, or recent participation in a clinical investigation that, in the opinion of the Investigator, would jeopardize subject safety or the integrity of the study results.
- On a special diet within 30 days prior to drug administration (e.g., liquid, protein, raw food diet).
- Have had a tattoo or body piercing within 30 days prior to drug administration.
- Have clinically significant findings in vital signs measurements at screening.
- Systolic blood pressure increase or decrease in value by more than 20 mmHg and/or diastolic blood pressure decrease in value by more than 10 mmHg, from supine or sitting to standing position during orthostatic blood pressure measurement taken at screening.
- Have clinically significant findings in a 12-lead ECG.
- Have clinically significant abnormal laboratory values and hemoglobin <135 g/L for males or <120 g/L for females at screening.
- Have significant diseases at screening.
- Have clinically significant findings from a physical examination.
Use of the following drugs within 14 days prior to drug administration:
- Alpha-adrenergic blocking drugs (e.g., phentolamine);
- Anti-arrhythmics;
- Beta-adrenergic blocking drugs (e.g., propranolol);
- Cardiac glycosides;
- Diuretics;
- Drugs having effect on cytochrome P450 (CYP450);
- Enzyme-altering drugs (e.g., barbiturates, phenothiazines, cimetidine, carbamazepine, etc.);
- Enzyme-modifying drugs known to induce/inhibit hepatic drug metabolism;
- Ergot alkaloids;
- Levothyroxine sodium;
- Monoamine oxidase inhibitors;
- Oral or topical corticosteroids;
- Phenylephrine;
- Reserpine-type or clonidine-type antihypertensives;
- Sodium cromoglycate; or
- Tricyclic antidepressants.
Use of the following drugs within 7 days prior to drug administration:
- Nasal decongestants;
- Nonsteroidal anti-inflammatory drugs (NSAIDs); or
- Oral or topical antihistamines.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 6 Healthy volunteers, sequence ABC
Three drug administrations to each subject, each administration on a separate day. treatment order: A B C |
Autoinjector for intramuscular, single-use, 0.3mg
Other Names:
Nasus Pharma nasal powder spray 3.6 mg, single use in one nostril
Other Names:
Nasus Pharma nasal powder spray 4.0 mg, single use in one nostril
Other Names:
|
Experimental: 6 Healthy volunteers, sequence BAC
Three drug administrations to each subject, each administration on a separate day. treatment order: B A C |
Autoinjector for intramuscular, single-use, 0.3mg
Other Names:
Nasus Pharma nasal powder spray 3.6 mg, single use in one nostril
Other Names:
Nasus Pharma nasal powder spray 4.0 mg, single use in one nostril
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Bioavailability of Epinephrine
Time Frame: -1 to 2 hours post dose
|
Plasma level of Epinephrine
|
-1 to 2 hours post dose
|
Blood pressure
Time Frame: -1 to 4 hours post dose
|
Pharmacodynamic response
|
-1 to 4 hours post dose
|
Heart rate
Time Frame: -1 to 4 hours post dose
|
Pharmacodynamic response
|
-1 to 4 hours post dose
|
Respiratory rate
Time Frame: -1 to 4 hours post dose
|
Pharmacodynamic response
|
-1 to 4 hours post dose
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
12-lead electrocardiogram
Time Frame: -2 up to 1 hour post dose
|
Safety
|
-2 up to 1 hour post dose
|
Adverse events
Time Frame: through study completion, an average of 3 weeks
|
Safety
|
through study completion, an average of 3 weeks
|
Nasal Mucosa health status
Time Frame: -1 hour until end of each dosing day, an average 3 weeks.
|
|
-1 hour until end of each dosing day, an average 3 weeks.
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Yoseph Caraco, Professor, Hadassah Medical Organization
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Immune System Diseases
- Hypersensitivity, Immediate
- Hypersensitivity
- Anaphylaxis
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Adrenergic alpha-Agonists
- Adrenergic Agonists
- Bronchodilator Agents
- Anti-Asthmatic Agents
- Respiratory System Agents
- Adrenergic beta-Agonists
- Sympathomimetics
- Vasoconstrictor Agents
- Mydriatics
- Epinephrine
- Racepinephrine
- Epinephryl borate
Other Study ID Numbers
- NP-006-Epinephrine
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Anaphylaxis
-
University of MichiganThe Gerber FoundationRecruiting
-
National Institute of Allergy and Infectious Diseases...RecruitingIdiopathic Anaphylaxis | Drug Anaphylaxis | Venom Anaphylaxis | Food AnaphylaxisUnited States
-
Central Hospital, Nancy, FranceSanofi; GlaxoSmithKline; Zambon SpA; Laboratoires URGO; Pierre Fabre Medicament; Bi... and other collaboratorsUnknownNeuromuscular Blocking Agents AnaphylaxisFrance
-
University of LeedsUnknownExercise AnaphylaxisUnited Kingdom
-
University Hospital, AngersRecruitingAnaphylaxis Caused by Hymenoptera Venom (Disorder)France
-
Ann & Robert H Lurie Children's Hospital of ChicagoNorthwestern University Feinberg School of MedicineCompleted
-
Mahidol UniversityCompletedWheat Allergy | Anaphylaxis Food | Anaphylaxis ExerciseThailand
-
Massachusetts General HospitalWithdrawnAnaphylaxis as a Result of Allergen or Venom ImmunotherapyUnited States
-
Merck Sharp & Dohme LLCCompleted
-
Siriraj HospitalMahidol UniversityCompleted
Clinical Trials on A: Epinephrine injection
-
Yuji KUMAGAIAetas Pharma Co. Ltd.CompletedHealthy VolunteersJapan
-
Kitasato UniversityAetas Pharma Co. Ltd.Completed
-
Kitasato UniversityAetas Pharma Co. Ltd.UnknownParoxysmal Atrial FibrillationJapan
-
China Academy of Chinese Medical SciencesHospital of Changchun University of Traditional Chinese MedicineUnknown
-
Brown, Theodore R., M.D., MPHEvergreen HealthcareCompletedErythema | MS (Multiple Sclerosis)United States
-
Ju Seok RyuCompletedCerebral PalsyKorea, Republic of
-
Seoul National University HospitalSeoul National University Bundang HospitalCompletedGoiter | Thyroid NeoplasmKorea, Republic of
-
Kyunghee University Medical CenterCompletedActive Peptic Ulcer Disease/GI BleedingKorea, Republic of
-
Kaohsiung Veterans General Hospital.Completed